Doctoral Student's Research Could Lead to Treatment of MS, Other Diseases | Eastern NC Now

Like many great scientific discoveries, Daniel Wilkinson's came almost by accident

ENCNow
    Publisher's note: The author of this post, Phillip Ramati, is a contributor to ECU News Services.

    Like many great scientific discoveries, Daniel Wilkinson's came almost by accident.

    As part of his doctoral research at East Carolina University, Wilkinson was working on a way of creating regulatory T cells, which are used in the treatment of autoimmune diseases, such as multiple sclerosis. But Mark Mannie, Wilkinson's supervisor and a professor in the Brody School of Medicine's Department of Microbiology and Immunology, said the results of Wilkinson's experiments kept coming out differently than what they were expecting.

    "He was getting information that didn't make any sense," Mannie said. "We were going over it, and it became apparent that what we were trying to do, the opposite was happening. And that became our 'Eureka!' moment. We then realized what was really going on and the potential of that."

    T cells are cells in the body that attack infectious organisms, such as viruses and parasites. But sometimes, the T cells become confused and will attack healthy parts of the body, leading to autoimmune conditions such as MS and Type 1 diabetes. Most people don't get autoimmune diseases because of a subset of T cells called "regulatory T cells" that protect the body.


Daniel Wilkinson, a doctoral student in ECU's Brody School of Medicine, has patented a process for replicating T cells for possible treatment of autoimmune diseases like MS and Type 1 diabetes. (Photos by Cliff Hollis)


    Scientists don't have a lot of knowledge when it comes to how regulatory T cells work, because they are very malleable and are difficult to cultivate and study.

    Wilkinson, a Charlotte native who got his bachelor's degree from the University of North Carolina at Chapel Hill, has figured out a way to replicate the regulatory T cells through an in-vitro process.

    "Scientists who study these cells get very frustrated because it's very difficult to grow these cells in a culture tube because they tend to be unstable in that type of environment, and we don't know why," Mannie said. "What Daniel has done is figure out a way to grow these cells in such a way that they are stable and maintain their identity. It's the foundation where we might be able to use these cells therapeutically to treat autoimmune disease."

    Wilkinson said, "With regulatory T cells, they can become unstable and actually make disease worse. I basically developed a method that allows us to generate a large number of these regulatory T cells and expand them in-vitro without them changing. To our knowledge, we're the first laboratory to accomplish this feat."

    Wilkinson has a provisional patent on the process, and he and Mannie are authoring a paper on their work. Ultimately, the goal is to license the technology to a biotech company that can use the process to create a treatment for autoimmune conditions.

    Mannie calls Wilkinson a model student and researcher.

    "He's very technically oriented - most of everything he does is a technical success, Mannie said. "He's what most people would like, more students like him, because he can plug away at his research and do such a nice job. 'Productive independence' is the key term."


Doctoral student Daniel Wilkinson and Mark Mannie, Wilkinson’s supervisor and a professor in East Carolina’s Department of Microbiology and Immunology


    As an undergraduate, Wilkinson wanted to study medicine to become a physician. But during his senior year, Wilkinson worked in an HIV research lab and that changed his outlook.

    "That really opened me up to a whole new world of discovery, so the idea that I could be the first person to discover something is kind of intriguing to me and what led me to follow this path."

    That's precisely what Wilkinson has accomplished with his work on regulatory T cells.

    "At first, it was kind of shocking," he said. "I didn't know what I had done exactly, how significant it was, until Dr. Mannie told me that people had been trying to do this for decades. It's kind of cool."
Go Back


Leave a Guest Comment

Your Name or Alias
Your Email Address ( your email address will not be published )
Enter Your Comment ( text only please )




Honors College Students Expand Worldview, Serve Others During Haiti Visit East Carolina University, School News, The Region, Neighboring Counties AAC Funds Research at ECU, Other Member Institutions


HbAD0

Latest Neighboring Counties

A North Carolina State Senate race is heading for a recount after the two pro-Trump Republicans come down to a two vote margin.
This is simply a failure of will, and we are here to help impose that will today, so that to me is the simple punchline," said State Treasurer Brad Briner. "I appreciate the leaders of Rocky Mount being here, but we need to get to a place where there is the will to fix a very, very serious problem.”
A federal judge will not issue an injunction blocking local Watauga County election districts created by the Republican-led North Carolina General Assembly.
The FBI has captured Alejandro “Alex” Rosales Castillo, who is on the 10 Most Wanted Fugitive list and wanted in connection with a 2016 murder in Charlotte.
A major redevelopment project planned in Morehead City has been scrapped following strong public opposition over the use of eminent domain.
In the coming months, the North Carolina Supreme Court will decide whether a class-action lawsuit can move forward against Raleigh over water and sewer impact fees.
Former congressman Wiley Nickel made his candidacy for the office of Wake County district attorney official this week, with his Tuesday announcement.
Groups representing North Carolina's travel and tourism industry support a lawsuit against Currituck County at the North Carolina Supreme Court.
Plaintiffs in a $16 million class-action lawsuit against Raleigh challenged the city's legal tactics in a new state Supreme Court filing.

HbAD1

 
 
Back to Top